Literature DB >> 30290369

Rules to activate CD8+T cells through regulating subunits of opioid receptors by methionine enkephalin (MENK).

Xue Jiao1, Xiaonan Wang2, Ruizhe Wang3, Jin Geng4, Ning Liu5, Hao Chen2, Noreen Griffin6, Fengping Shan7.   

Abstract

The goal of this work was to investigate how MENK could regulate the functions of CD8+T cells and to explore the relationship between this regulation and opioid receptor expression. Our results showed that the opioid receptors presented on the cell menbrane of CD8+T cells were MOR and DOR. MENK promoted the expression of opioid receptors as well as the elevation of the surface molecules such as CD28, PD-1, CTLA-4 and FasL and intracellular granzyme B. Selectively blocking the MOR by CTAP or DOR by NTI could result in inhibition of the corresponding CD8+T cells proliferation and the expressions of surface molecules. In addition, non-selectively blocking both MOR and DOR by NTX could further impair the functions and proliferation of CD8+T cells. Our currently data indicated that MENK could play a vital role in immune functions via precise regulation to subunits of opioid receptors.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD8(+)T cells; CTAP; Methionine enkephalin (MENK); Naltrexone hydrochloride; Naltrindole hydrochloride; Opioid receptor

Mesh:

Substances:

Year:  2018        PMID: 30290369     DOI: 10.1016/j.intimp.2018.09.040

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  2 in total

1.  Chronic Methadone Use Alters the CD8+ T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli.

Authors:  Claire Mazahery; Bryan L Benson; Angélica Cruz-Lebrón; Alan D Levine
Journal:  J Immunol       Date:  2020-01-22       Impact factor: 5.422

Review 2.  Potential neuro-immune therapeutic targets in irritable bowel syndrome.

Authors:  Maite Casado-Bedmar; Åsa V Keita
Journal:  Therap Adv Gastroenterol       Date:  2020-04-09       Impact factor: 4.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.